# Healthy Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/healthy-biotech

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.healthybiotech.com.cn
- Latest round: Series A (Aug 29, 2024)
- Investors on record: 1

## About

Founded in 2019 and based in Wuhan, China, Healthy Biotech is a biotech company that focuses on developing individualised molecular diagnostic reagents for blood diseases. In August 2024, the firm closed a series A funding.  The company is affiliated with ComSun Global. It has 40,000 square metres of laboratory and 3,300 square metres of GMP plant.

The company's main products include PCR products, Sanger products and NGS products. PCR products include HemaFus BCR-ABL1 (P210 type) fusion gene high sensitivity detection kit and HemaMut human JAK2 gene V617F mutation detection kit. The company also provides auxiliary reagents and laboratory consumables. The company's products are used in diseases such as leukaemia, malignant lymphoma and multiple myeloma.

The company's revenue is generated by providing individualised molecular diagnostic reagents for blood disorders.

The company will use the series A funding to enhance the translation of its research and development in the field of haematology clinical tests into standardised in vitro diagnostic kits, as well as its globalisation strategy.

## Funding rounds

- Series A, Aug 29, 2024 — Rivercity Investment

## Investors

- Rivercity Investment (https://capitalatlas.ai/funds/rivercity-investment) — Series A